Skip to main content
SpringerLink
Log in

The Clinical Application of Plasma EBV DNA Assay in NPC

  • Chapter
  • First Online:
Medical Radiology

Part of the book series: Medical Radiology

Abstract

Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus (EBV)-associated carcinoma of epidermoid origin. There are many strong evidences showing that quantification of plasma EBV DNA level is an ideal tumor marker for NPC. The EBV DNA blood test data can provide valuable supplement information to the current TNM staging system, aids in risk grouping, early evaluation of treatment response, and treatment outcome prediction. In addition, post-RT continuous monitoring of plasma EBV DNA can detect recurrence several months in advance, guide appropriate and early salvage treatment for the affected cases. Application of EBV DNA-guided approaches can achieve individualized tailor-made therapy for each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Alami IE, Gihbid A, Charoute H et al (2022) Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis. Pan Afr Med J 41:6

    Google Scholar 

  • Chan AT, Lo YM, Zee B et al (2002) Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94(21):1614–1619

    Google Scholar 

  • Chan KCA, Zhang J, Chan ATC et al (2003) Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63(9):2028–2032

    Google Scholar 

  • Chan SL, Hui EP, Leung SF et al (2006) Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. BMC Cancer 6:259

    Google Scholar 

  • Chan KC, Hung EC, Woo JK et al (2013) Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 119(10):1838–1844

    Google Scholar 

  • Chan KCA, Woo JKS, King A et al (2017) Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 377(6):513–522

    Google Scholar 

  • Chan ATC, Hui EP, Ngan RKC et al (2018) Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol 36:3091–3100

    Google Scholar 

  • Chan SK, Chan SY, Choi HCW et al (2020) Prognostication of half-life clearance of plasma EBV DNA in previously untreated non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy. Front Oncol 10:1417

    Google Scholar 

  • Chang YS, Tyan YS, Liu ST et al (1990) Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol 28(11):2398–2402

    Google Scholar 

  • Chao TY, Chow KC, Chang JY et al (1996) Expression of Epstein-Barr virus-encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma. Cancer 78(1):24–29

    Google Scholar 

  • Chen CL, Wen WN, Chen JY et al (1993) Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. Intervirology 36(2):91–98

    Google Scholar 

  • Chen TY, Tsai ST, Jin YT et al (1999) Bone marrow metastasis in nasopharyngeal cancer: early detection using EBER1 in situ hybridization. Anticancer Res 19(1b):885–888

    Google Scholar 

  • Chen FP, Huang XD, Lv JW et al (2020) Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma. Cancer 126:2163–2173

    Google Scholar 

  • Chen FP, Luo YS, Chen K et al (2021a) Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma. Eur J Cancer 151:63–71

    Google Scholar 

  • Chen YP, Liu X, Zhou Q et al (2021b) Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 398(10297):303–313

    Google Scholar 

  • Guo R, Tang LL, Mao YP et al (2019) Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer 125(1):79–89

    Google Scholar 

  • Han BL, Xu XY, Zhang CZ et al (2012) Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev 13:2577–2581

    Google Scholar 

  • He SS, Wang Y, Bao Y et al (2018) Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study. Cancer Med 7(4):1110–1117

    Google Scholar 

  • Hou X, Chong Z, Guo Y et al (2011) Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol 23:128–133

    Google Scholar 

  • Hsiao JR, Jin YT, Tsai ST (2002) Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer 94:723–729

    Google Scholar 

  • Hsu CL, Chang KP, Lin CY et al (2012) Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck 34(8):1064–1070

    Google Scholar 

  • Hsu CL, Chan SC, Chang KP et al (2013) Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. Oral Oncol 49(6):620–625

    Google Scholar 

  • Huang CL, Sun ZQ, Guo R et al (2019) Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 104(2):355–361

    Google Scholar 

  • Hui EP, Li WF, Ma BB et al (2020) Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol 31(6):769–779

    Google Scholar 

  • Ji MF, Huang QH, Yu X et al (2014) Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in southern China. Cancer 120(9):1353–1360

    Google Scholar 

  • Kim KY, Le QT, Yom SS et al (2017) Current state of PCR-based Epstein-Barr virus DNA testing for nasopharyngeal cancer. J Natl Cancer Inst 109(4). https://doi.org/10.1093/jnci/djx007

  • Kitpanit S, Jittapiromsak N, Sriyook A et al (2019) Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein–Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial. Jpn J Clin Oncol 49(12):1100–1113

    Google Scholar 

  • Lai L, Chen XY, Zhang CX et al (2021) Pretreatment plasma EBV-DNA load guides induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer: a meta-analysis. Front Oncol 10:610787

    Google Scholar 

  • Lam WKJ, Jiang P, Chan KCA et al (2018) Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 115(22):E5115–E5124

    Google Scholar 

  • Le QT, Jones CD, Yau TK et al (2005) A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res 11:5700–5707

    Google Scholar 

  • Le QT, Zhang Q, Cao H et al (2013) An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res 19(8):2208–2215

    Google Scholar 

  • Lee WY, Hsiao JR, Jin YT et al (2000) Epstein-Barr virus detection in neck metastases by in-situ hybridization in fine-needle aspiration cytologic studies: an aid for differentiating the primary site. Head Neck 22(4):336–340

    Google Scholar 

  • Lee VH, Kwong DL, Leung TW et al (2017) Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. Oncotarget 8(3):5292–5308

    Google Scholar 

  • Lee VH, Kwong DL, Leung TW et al (2019) The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer 144(7):1713–1722

    Google Scholar 

  • Leung SF, Zee B, Ma BB et al (2006) Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 24(34):5414–5418

    Google Scholar 

  • Leung SF, Chan KC, Ma BB et al (2014) Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 25(6):1204–1208

    Google Scholar 

  • Li WF, Zhang Y, Huang XB et al (2017) Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy. Chin J Cancer 36(1):87

    Google Scholar 

  • Li WZ, Wu HJ, Lv SH et al (2021) Assessment of survival model performance following inclusion of Epstein-Barr virus DNA status in conventional TNM staging groups in Epstein-Barr virus-related nasopharyngeal carcinoma. JAMA Netw Open 4(9):e2124721

    Google Scholar 

  • Li XY, Luo DH, Guo L et al (2022) Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial. J Clin Oncol 40(11):1163–1173

    Google Scholar 

  • Liang H, Lv X, Wang L et al (2018) The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area. Ther Adv Med Oncol 10:1758835918782331

    Google Scholar 

  • Liang SB, Zhang N, Chen DM et al (2019) Prognostic value of gross tumor regression and plasma Epstein Barr virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma. Radiother Oncol 132:223–229

    Google Scholar 

  • Lin JC, Wang WY, Chen KY et al (2004) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350(24):2461–2470

    Google Scholar 

  • Lin JC, Wang WY, Liang WM et al (2007) Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 68:1342–1348

    Google Scholar 

  • Lin JC, Wang WY, Liu YC (2018) Impacts of plasma EBV DNA load during different time-points of induction chemotherapy plus radiotherapy for nasopharyngeal carcinoma. J Clin Oncol 36(15 Suppl):6058

    Google Scholar 

  • Liu Y, Fang Z, Liu L et al (2011) Detection of Epstein-Barr virus DNA in serum or plasma for nasopharyngeal cancer: a meta-analysis. Genet Test Mol Biomarkers 15:495–502

    Google Scholar 

  • Liu TB, Zheng ZH, Pan J et al (2017a) Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis. Clin Invest Med 40(1):E1–E12

    Google Scholar 

  • Liu YC, Wang WY, Twu CW et al (2017b) Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. Oral Oncol 64:15–21

    Google Scholar 

  • Liu W, Chen G, Gong X et al (2021) The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis. Cancer Cell Int 21:164

    Google Scholar 

  • Lo YMD, Chan LYS, Lo K-W et al (1999a) Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59:1188–1191

    Google Scholar 

  • Lo YMD, Chan LYS, Chan ATC et al (1999b) Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59:5452–5455

    Google Scholar 

  • Lo YM, Leung SF, Chan LY et al (2000) Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann N Y Acad Sci 906:99–101

    Google Scholar 

  • Lv JW, Zhou GQ, Li JX et al (2017) Magnetic resonance imaging-detected tumor residue after intensity-modulated radiation therapy and its association with post-radiation plasma Epstein-Barr virus deoxyribonucleic acid in nasopharyngeal carcinoma. J Cancer 8(5):861–869

    Google Scholar 

  • Ma BB, King A, Lo YM et al (2006) Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:714–720

    Google Scholar 

  • Ma B, Hui EP, King A et al (2018) Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. Br J Cancer 118(8):1051–1055

    Google Scholar 

  • Macdonald MR, Freeman JL, Hui MF et al (1995) Role of Epstein-Barr virus in fine-needle aspirates of metastatic neck nodes in the diagnosis of nasopharyngeal carcinoma. Head Neck 17(6):487–493

    Google Scholar 

  • Mai HQ, Yang JH, Guo SS et al (2022) Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: a single-arm, phase II trial. J Clin Oncol 40(16 Suppl):6002

    Google Scholar 

  • Makitie AA, Reis PP, Irish J et al (2004) Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study. Head Neck 26(9):815–822

    Google Scholar 

  • Miao JJ, Wang L, Tan SH et al (2022) Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol 8(12):1776–1785

    Google Scholar 

  • Mutirangura A, Pornthanakasem W, Theamboonlers A et al (1998) Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res 4:665–669

    Google Scholar 

  • Pathmanathan R, Prasad U, Chandrika G et al (1995a) Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 146(6):1355–1367

    Google Scholar 

  • Pathmanathan R, Prasad U, Sadler R et al (1995b) Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333(11):693–698

    Google Scholar 

  • Peng H, Chen L, Zhang Y et al (2016a) Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Oncotarget 7(17):24208–24216

    Google Scholar 

  • Peng H, Guo R, Chen L et al (2016b) Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. Sci Rep 6:22000

    Google Scholar 

  • Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A (2000) Epstein-Barr viral DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 6:1046–1051

    Google Scholar 

  • Song C, Yang S (2013) A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of nasopharyngeal carcinoma. Pak J Med Sci 29:885–890

    Google Scholar 

  • Sun D, Yang Z, Fu Y et al (2014) Clinical value of serum Epstein-Barr virus DNA assay in the diagnosis of nasopharyngeal carcinoma. Tumor Biol 35:8787–8793

    Google Scholar 

  • Tsai ST, Jin YT, Su IJ (1996) Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization. A correlation with WHO histologic subtypes. Cancer 77(2):231–236

    Google Scholar 

  • Twu CW, Wang WY, Liang WM et al (2007) Comparison of the prognostic impact between serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 67:130–137

    Google Scholar 

  • Twu CW, Wang WY, Chen CC et al (2014) Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys 89(1):21–29

    Google Scholar 

  • Wang WY, Twu CW, Chen HH et al (2010) Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 16(3):1016–1024

    Google Scholar 

  • Wang WY, Twu CW, Lin WY et al (2011) Plasma Epstein-Barr virus DNA screening followed by 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer 117(19):4452–4459

    Google Scholar 

  • Wang WY, Lin PJ, Lin JC (2012) Circulating EBV DNA and 18F-FDG PET scan in the diagnosis and monitoring of nasopharyngeal carcinoma. J Formos Med Assoc 111(2):118–119

    Google Scholar 

  • Wang WY, Twu CW, Chen HH et al (2013) Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer 119(5):963–970

    Google Scholar 

  • Wang WY, Lin TY, Twu CW et al (2016) Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA. Oncotarget 7(27):42608–42616

    Google Scholar 

  • Wang FH, Wei XL, Feng J et al (2021) Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol 39(7):704–712

    Google Scholar 

  • Wu CF, Lin L, Mao YP et al (2021) Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC Med 19:193

    Google Scholar 

  • Xie XL, Ren YP, Wang K, Yi B (2019) Molecular prognostic value of circulating Epstein-Barr viral DNA in nasopharyngeal carcinoma: a meta-analysis of 27,235 cases in the endemic area of southeast Asia. Genet Test Mol Biomarkers 23(7):448–459

    Google Scholar 

  • Xu JY, Wei XL, Ren C et al (2022) Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 immunotherapy. JAMA Netw Open 5(3):e220587

    Google Scholar 

  • Yang ZC, Du CC, Liu LT et al (2022) The prognostic role of plasma Epstein-Barr virus DNA levels in the middle of intensity modulated radiation therapy to guide cisplatin dose recommendation in concurrent chemoradiation therapy in patients with locally advanced nasopharyngeal carcinoma: a large cohort study. Adv Radiat Oncol 7(3):100908

    Google Scholar 

  • Yip TT, Ngan RK, Fong AH et al (2014) Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol 50(6):527–538

    Google Scholar 

  • Zhang W, Chen Y, Chen L et al (2015) The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era? A systematic review and meta-analysis of 7836 cases. Medicine 94(20):e845

    Google Scholar 

  • Zhang L, Tang LQ, Chen QY et al (2016a) Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. Oncotarget 7(5):6221–6230

    Google Scholar 

  • Zhang J, Shu C, Song Y et al (2016b) Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: a meta-analysis. Medicine 95(40):e5130

    Google Scholar 

  • Zhao FP, Liu X, Chen XM et al (2015) Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma. Oncol Lett 10(5):2888–2894

    Google Scholar 

  • Zong JF, Liu YH, Liang QD et al (2021) Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma. Oral Oncol 118:105313

    Google Scholar 

  • Zong JF, Ji PG, Lin C et al (2022) Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma. Oral Oncol 131:105972

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan

    Jin-Ching Lin

Authors
  1. Jin-Ching Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin-Ching Lin .

Ethics declarations

None declared.

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lin, JC. (2023). The Clinical Application of Plasma EBV DNA Assay in NPC. In: Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2023_458

Download citation

  • DOI: https://doi.org/10.1007/174_2023_458

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

Publish with us

Policies and ethics

Search

Navigation